Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I1PS
|
|||
| Drug Name |
Dasatinib
|
|||
| Synonyms |
Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic myeloid leukaemia [ICD-11: 2A20; ICD-10: C92.7; ICD-9: 205.1] | Approved | [1] | |
| Middle East Respiratory Syndrome (MERS) [ICD-11: 1D64] | Investigative | [2] | ||
| Severe acute respiratory syndrome (SARS) [ICD-11: 1D65] | Investigative | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Bristol Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H26ClN7O2S
|
|||
| Canonical SMILES |
CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO
|
|||
| InChI |
1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)
|
|||
| InChIKey |
ZBNZXTGUTAYRHI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 302962-49-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10061134, 12015788, 14859389, 17397755, 17422520, 36127155, 46505143, 46513626, 47883136, 48429642, 49742622, 50070229, 50070567, 50071309, 50100097, 50125840, 52995488, 53799228, 56312240, 56312839, 56313127, 56373968, 56459420, 57288451, 57354110, 57551950, 74374210, 85246174, 87235888, 87357382, 93581026, 99381604, 99437986, 103501621, 103905543, 111644212, 117418208, 117695728, 118050493, 119503515, 124361516, 124756940, 124893650, 124893651, 124893652, 125001912, 125163747, 125264620, 125347447, 126624063
|
|||
| ChEBI ID |
CHEBI:49375
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.